- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07706556
Pilot SMART of a Remotely Delivered, Adaptive Physical Activity Intervention for Breast Cancer Survivors
A Pilot Sequential, Multiple Assignment, Randomized Trial (SMART) of a Remotely Delivered, Adaptive Physical Activity Intervention for Breast Cancer Survivors
The goal of this clinical trial is to evaluate the feasibility of randomizing participants to a "step-up" intervention pathway when they perform <150 minutes of MVPA at the 6-week data collection burst. Participants who performed <150 minutes of MVPA at the 6-week data collection burst will be randomized to either continue with the standard intervention or advance to the step-up intervention. The main questions it aims to answer are:
- What percentage of participants who are eligible for the intervention phase enroll in the intervention phase?
- Will participants assigned to the "step-up" intervention pathway demonstrate equal or greater rates of study retention and intervention engagement relative to those assigned to the standard intervention arm?
- What percentage of the sample is performing >150 minutes accelerometer measured MVPA/week at the intervention mid-point (week 6-data collection burst) and end-of-study (week 12-data collection burst)?
- Do at least 50% of participants assigned to the "step-up" intervention pathway achieve a clinically meaningful volume of weekly MVPA by 12-weeks follow-up?
All participants will:
- Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription.
- Participate in three meetings with the interventionist (an exercise specialist) meant to help them get started increasing weekly exercise. These meetings are the same for all participants.
- Be asked to wear an activity monitor and respond to brief surveys for 10 consecutive days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.
Some participants (those performing <150 minutes of MVPA at the 6-week data collection burst) will be assigned to the step-up intervention pathway. Participants assigned to the step-up intervention pathway will complete 3 additional follow-up meetings with the interventionist. During these meetings, the interventionist will help participants identify opportunities to be more active, set goals, and problem solve barriers to action.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Courtney J Stevens, PhD
- Phone Number: 6036509643
- Email: courtney.j.stevens@dartmouth.edu
Study Contact Backup
- Name: Aislinn Mitcham, BA
- Phone Number: 6036466545
- Email: aislinn.e.mitcham@hitchcock.org
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Recruiting
- Dartmouth-Hitchcock Clinic
-
Contact:
- Courtney J Stevens, PhD
- Phone Number: 603-646-5451
- Email: courtney.j.stevens@dartmouth.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-≥18 years old
- Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer
- <60 mins/week moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months
- Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods
- Willing to wear the ActiGraph monitor during assessment periods
- Access to internet to complete REDCap survey assessments
Exclusion Criteria:
- Non-English speaking/not able to read English
- Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+)
- Currently pregnant
- History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium)
- Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8)
- Evidence of moderate-severe cognitive impairment (indicated by a score < 3 on a 6-item cognitive screener)
- Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Effort-based Exercise Prescription (RPE-Rx) Standard
|
Core intervention content will be delivered during the Visit 1, 1-month, and 2-month-check-in meetings.
Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed.
All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type).
The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same for all participants.
All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines.
All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
|
|
Experimental: Affect-based Exercise Prescription (Affect-Rx) Standard
|
Core intervention content will be delivered during the Visit 1, 1-month, and 2-month-check-in meetings.
Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed.
All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type).
The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same for all participants.
All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines.
All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
Participants assigned to Affect-Rx will receive instructions to "select a pace of exercise that makes you feel as good as possible."
The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to "stay in the green zone" on the Feeling Scale.
|
|
Active Comparator: Effort-based Exercise Prescription (RPE-Rx) Step-Up
|
Participants assigned to RPE-Rx will receive instructions to "select a pace that would make it challenging for you to carry on more than a short conversation."
The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to "stay in the green zone" on the RPE Scale.
Core intervention content will be delivered during the Visit 1, 1-month, and 2-month-check-in meetings.
Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed.
All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type).
The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same for all participants.
All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines.
All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
Core intervention content will be delivered during check-in meetings scheduled during study weeks 7, 8, 9, and 10.
During these visits, the interventionist will work with the participant to set weekly goals and problem-solving barriers to action.
All participants will continue to receive instructions to follow their assigned exercise prescription (Affect-based Exercise Prescription or Effort-based exercise prescription).
The step-up intervention calls are delivered the same regardless to which exercise prescription format the participant is assigned.
|
|
Experimental: Affect-based Exercise Prescription (Affect-Rx) Step-Up
|
Core intervention content will be delivered during the Visit 1, 1-month, and 2-month-check-in meetings.
Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed.
All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type).
The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same for all participants.
All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines.
All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
Participants assigned to Affect-Rx will receive instructions to "select a pace of exercise that makes you feel as good as possible."
The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to "stay in the green zone" on the Feeling Scale.
Core intervention content will be delivered during check-in meetings scheduled during study weeks 7, 8, 9, and 10.
During these visits, the interventionist will work with the participant to set weekly goals and problem-solving barriers to action.
All participants will continue to receive instructions to follow their assigned exercise prescription (Affect-based Exercise Prescription or Effort-based exercise prescription).
The step-up intervention calls are delivered the same regardless to which exercise prescription format the participant is assigned.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study Retention at 6-weeks Follow-up
Time Frame: 6-weeks follow-up assessment.
|
Number of participants who complete the 6-week follow-up assessment out of the number of participants who enroll in the study.
|
6-weeks follow-up assessment.
|
|
Study Retention at 12-weeks Follow-up
Time Frame: 12-weeks follow-up assessment.
|
Number of participants who complete the 12-week follow-up assessment out of the number of participants who enroll in the study.
|
12-weeks follow-up assessment.
|
|
Rate of Intervention Enrollment
Time Frame: Baseline assessment.
|
Number of participants who enroll in the intervention phase out of the number of participants who are eligible for the intervention phase
|
Baseline assessment.
|
|
Intervention Engagement
Time Frame: 12-weeks follow-up assessment.
|
Number of intervention sessions completed out of the number of intervention sessions scheduled
|
12-weeks follow-up assessment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satisfaction With Study Participation as Measured by the Participant Satisfaction Questionnaire
Time Frame: 12-weeks follow-up assessment.
|
An 8-item self-report questionnaire used to assess participant satisfaction with study participation using a Likert scale ranging from 1 to 4 .
Scores are summed and then averaged; total scores range from 1- 4. Higher scores indicate greater satisfaction.
|
12-weeks follow-up assessment.
|
|
Change in Voluntary Exercise Behavior Measured Using The Voluntary Exercise Questionnaire
Time Frame: Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
A 6-item self-report measure of exercise performed over the last month and week.
Two items range from 1 (never) to 7 (often) and four items range from 0 (0 days per week) to 7 (7 days per week).
Total scores range from 2-21.
Higher scores reflect higher levels of voluntary exercise behavior.
|
Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
|
Change in Physical Activity using The International Physical Activity Questionnaire (IPAQ)-Short Form
Time Frame: Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
A 7-item self-report measure calculating the amount of health-related vigorous and moderate-intensity physical activity as well as sitting time performed by adult participants over a one-week period.
The number of minutes per day participants report for 3 categories vigorous, moderate, and walking activities are multiplied by the average metabolic equivalent (METs) for each category (8.0 METs, 4.9 METs, and 3.3 METs, respectively).
Scores for each category are summed to calculate a physical activity score for the past week quantified as total MET values.
Higher METS demonstrate a higher total volume of physical activity completed in the prior week.
MET values between 0-599 are considered "low active," MET values between 600-1499 are considered "moderately active," and MET values 1500 or higher are considered "High active."
This measure also assesses participants' total sitting time in the past week.
Total number of minutes reported for sitting time is not part of the physical activity
|
Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
|
Change in Physical Activity Category Completed in the Past Month Measured Using the Stanford Leisure-Time Activity Categorical Item (L-Cat)
Time Frame: Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
A single item self-report measure that present six statements describing various levels of monthly physical activity.
Response options range from 1 (I did not do much physical activity) to 6 (I did vigorous activities almost daily).
Total scores range from 1-6.
Higher scores reflect more vigorous, more frequent physical activities completed in the past month.
|
Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
|
Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 2 Weeks Follow-up
Time Frame: Time Frame: 2-weeks follow-up assessment.
|
The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors.
Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days.
Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.
|
Time Frame: 2-weeks follow-up assessment.
|
|
Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 6 Weeks Follow-up.
Time Frame: Time Frame: 6-weeks follow-up assessment
|
The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors.
Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days.
Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.
|
Time Frame: 6-weeks follow-up assessment
|
|
Average Minutes of Daily Moderate-vigorous Physical Activity Measured Using the ActiGraph wGT3X-BT Accelerometer at 12 Weeks Follow-up
Time Frame: [Time Frame: 12-weeks follow-up assessment.
|
The research grade ActiGraph wGT3X-BT model is a valid measure of physical activity intensity and duration among multiple populations, including breast cancer survivors.
Minutes of moderate-vigorous physical activity will be collected from the ActiGraph wGT3X-BT every day for 10-days.
Average minutes of moderate-vigorous physical activity completed per day of valid wear time will be calculated.
|
[Time Frame: 12-weeks follow-up assessment.
|
|
Intervention Acceptability Measured Using the Treatment Acceptability and Preferences (TAP) Measure
Time Frame: 12-weeks follow-up assessment.
|
A 4-item self-report questionnaire used to measure intervention acceptability using a Likert scale ranging from 0 (not at all) to 4 (very much).
Total scores range from 0 - 16. Higher scores indicate greater acceptability.
|
12-weeks follow-up assessment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change Overtime in Cancer-related Fatigue Measured Using the PROMIS Fatigue Short Form 8a
Time Frame: Baseline and 12-weeks follow-up assessments.
|
An 8-item self-report measure with response options ranging from 1 (not at all) to 5 (very much) and fatigue interference ranging from 1 (never) to 5 (always) over the past 7 days.
Total scores range from 8 - 40.
Higher scores reflect more fatigue.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Health-related Quality of Life Measured Using the PROMIS Global Health Scale
Time Frame: Baseline and 12-weeks follow-up assessments.
|
A 10-item self-report measure with response options ranging from 1 (poor/never/not at all) to 5 (excellent/completely/always) for items 1-9 and 0 (no pain) to 10 (worst pain imaginable) for the item 10.
Total scores range from 9 - 45. Higher scores represent better health-related quality of life.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Physical Functioning Measured Using The PROMIS Physical Function Short Form 8a
Time Frame: Baseline and 12-weeks follow-up assessments.
|
An 8-item self-report measure with response options ranging from 1 (unable to do) to 5 (without any difficulty) and the degree to which health limits specific activities on a scale from 1 (cannot do) to 5 (not at all).
Total scores range from 8 - 40.
Higher scores reflect better physical function.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Anxiety measured using The PROMIS Anxiety Form
Time Frame: Baseline and 12-weeks follow-up assessments.
|
An 8-item self-report measure with response options ranging from 1 (never) to 5 (always).
Total scores range from 8 - 40.
Higher scores reflect higher levels of anxiety.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Depressive Symptoms using The PROMIS Depression Form
Time Frame: Baseline and 12-weeks follow-up assessments.
|
An 8-item self-report measure with response options ranging from 1 (never) to 5 (always).
Total scores range from 8 - 40.
Higher scores reflect higher levels of depressive symptoms.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Sleep Disturbance using The PROMIS Sleep Disturbance Scale
Time Frame: Baseline and 12-weeks follow-up assessments.
|
An 8-item self-report measure with response options indicating the level of sleep disturbance a participant may experience.
The first question asks about sleep quality and ranges from 1 (very good) to 5 (very poor).
Questions 2-8 further inquire about the specifics of the sleep experience, ranging from 1 (not at all) to 5 (very much).
Total scores range from 8 - 40.
Higher scores reflect a greater degree of sleep disturbance or poorer quality of sleep.
|
Baseline and 12-weeks follow-up assessments.
|
|
Change Overtime in Intentions for Exercise Measured Using The Exercise Intentions Scale
Time Frame: Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
A 5-item self-report measure of intentions to exercise in the next week.
Response options range from 1 (not at all likely) to 7 (very likely).
Responses are summed and then averaged; total scores range from 1-7.
Higher scores represent stronger intentions to exercise in the next week.
|
Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
|
Change Overtime in Physical Activity Enjoyment using the Physical Activity Enjoyment Scale-Short form (PACE-S)
Time Frame: Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
A 4-item self-report measure with response options ranging from 1 (Strongly disagree) to 5 (Strongly agree).
Total scores range from 4 - 20.
Higher scores reflect higher levels of pleasure when performing physical activity.
|
Baseline, 6-weeks follow-up, and 12-weeks follow-up.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY02000934_2b
- Dartmouth Cancer Center Pilot (Other Grant/Funding Number: Dartmouth Cancer Center Pilot Awards)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Effort-based exercise prescription
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)Recruiting
-
Istituti Clinici Scientifici Maugeri SpACompletedRehabilitation | Post-cardiac SurgeryItaly
-
University of New MexicoActive, not recruitingPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)United States
-
University of New MexicoActive, not recruiting
-
Peking University Third HospitalNot yet recruiting
-
Peking University People's HospitalNot yet recruiting
-
Georgia Institute of TechnologyIcahn School of Medicine at Mount Sinai; Emory UniversityNot yet recruitingDepression | AnhedoniaUnited States
-
Royal Cornwall Hospitals TrustRecruitingBariatric Surgery | PrehabilitationUnited Kingdom
-
Jing MaNot yet recruitingCoronary Heart DiseaseChina
-
Endocrinology and Clinical Nutrition Research Center...CompletedFrail Elderly Syndrome | SarcopeniaSpain